DPP-4 Therapy Center

Type 2 patients who used saxagliptin or sitagliptin had similar risks for heart failure as those who received other anti-hyperglycemic agents, according to a retrospective cohort study.

A secondary analysis of the TECOS trial affirms sitagliptin does not increase heart failure risk for patients with type 2 diabetes.

New alert issued for type 2 patients taking saxagliptin (Onglyza, AstraZeneca) and alogliptin (Nesina, Takeda).

New study suggests possible role for DPP-4 inhibitor in reducing CVD risk.

Study results indicate that risk increased similarly for all glucose lowering agents.

New study suggests triple therapy improves glycemic control.

Oral med approved by the Japanese Pharmaceuticals and Medical Devices Agency (PDMA) for type 2 treatment.

Combination does not alter myocardial infarction, hospitalization risks.

Dr. Christophe Arbet-Engels talks about some of the diabetes drugs in Boehringer Ingelheim’s pipeline including several compounds with liagliptin which BI is continuing to study and expand their knowledge of. They have looked at data in the past on African Americans and are now examining data of the drug’s efficacy in …

  In this week’s Homerun Slides, a closer look at the workings and efficacy of DPP-4 inhibitors…   To download the complete set in PowerPoint format, just use this link: The Present and Future of Insulin Therapy in the Era of Pathophysiologic Treatment of T2DM, Part 8 Catch up on past …